Delcath Systems Completes Executive Management Team with Strategic New Hires
23 Oktober 2009 - 12:30PM
PR Newswire (US)
NEW YORK, Oct. 23 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
(NASDAQ: DCTH), a medical technology company testing its
proprietary treatment method for primary and metastatic cancers to
the liver, completed the expansion of its executive management team
with three new hires. Armand "Chuck" Frigon will join Delcath as
Vice President for Operations on November 2, 2009; Agustin Gago
will join as Executive Vice President for Global Sales and
Marketing, also on November 2; and John Purpura will join as
Executive Vice President for Regulatory Affairs and Quality
Assurance on November 16, 2009. These are all new positions. "With
enrollment in our Phase III study of the Delcath PHP System(TM) for
the regional delivery of melphalan to the liver now complete, we
are focused on preparing for FDA submission in 2010, international
licensing and manufacturing," said Eamonn Hobbs, President and CEO
of Delcath. "We have brought on three exceptional executives to
lead our efforts in these areas and deliver the additional skills
and experience we need in executive management to transition from
an R&D to a commercial enterprise. We look forward to working
side-by-side with Chuck, Agustin and John to generate still greater
momentum in our business." John Purpura, 48, was most recently with
E-Z-EM as Vice President and then Executive Director of
International Regulatory Affairs from 2007 to 2008, and Head of
Regulatory Affairs for North America and Latin America from 2008 to
the present. Prior to E-Z-EM, Mr. Purpura had an 11-year career
with Sanofi-Aventis in progressively more senior regulatory CMC
responsibilities, ultimately serving as Associate Vice President
for Regulatory CMC from 2005 to 2007. Prior to Sanofi, Mr. Purpura
held various quality and regulatory management roles with Bolar
Pharmaceuticals, Luitpold Pharmaceuticals, and Eon Labs
Manufacturing from 1985 to 1995. He earned a MS in Management &
Policy and BS degrees in Chemistry and Biology at the State
University of New York at Stony Brook. Before joining Delcath,
Agustin Gago had been Vice President for International Oncology
Surgery Sales at AngioDynamics, Inc since 2008. Prior to
AngioDynamics, he was Vice President for the Global GI Business
Unit at E-Z-EM from 2002 and Vice President of International
Operations from 1998. He earned his BS in Business Management at
Hofstra University and diplomas in International and Export
Practices at universities overseas. Armand Frigon is known as
Chuck. He has been general manager of Sterigenics International
since 2007. Prior to Sterigenics, Mr. Frigon was with Tyco
Healthcare since 1988 as materials manager in its disposable
medical device unit. He was Production and Inventory Control
Manager and Senior Industrial Engineer at Mallinkrodt Anesthesia
Products from 1983 to 1988 and Production Manager, Plant
Engineering Manager, and Plant Industrial Engineer at CR Bard from
1979 to 1982. He earned a BA in Operations Management from
Excelsior College. Delcath also recently announced the additions of
David McDonald as Chief Financial Officer and Dr. Krishna Kandarpa
as Chief Medical Officer and EVP of Research and Development. About
Delcath Systems, Inc. Delcath Systems, Inc. is a medical device
company specializing in cancer treatment. The Company is testing a
proprietary, patented drug delivery system for the treatment of
liver cancers. Delcath's novel drug delivery platform is testing
the delivery of ultra-high doses of anti-cancer drugs to the liver
while preventing these high doses of drug from entering the
patient's bloodstream. The Company maintains a broad intellectual
property portfolio on a worldwide basis including the U.S., Europe,
Asia and Canada. For more information, please visit the Company's
website at http://www.delcath.com/. The Private Securities
Litigation Reform Act of 1995 provides a safe harbor for
forward-looking statements made by the Company or on its behalf.
This news release contains forward-looking statements, which are
subject to certain risks and uncertainties that can cause actual
results to differ materially from those described. Factors that may
cause such differences include, but are not limited to,
uncertainties relating to our ability to successfully complete
clinical trials and secure regulatory approval of our current or
future drug-delivery system and uncertainties regarding our ability
to obtain financial and other resources for any research,
development and commercialization activities. These factors, and
others, are discussed from time to time in our filings with the
Securities and Exchange Commission. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date they are made. We undertake no obligation to publicly
update or revise these forward-looking statements to reflect events
or circumstances after the date they are made. DATASOURCE: Delcath
Systems, Inc. CONTACT: investors, Doug Sherk, Stacey Fisher, Mike
Pollack, +1-415-896-6820; or media, Steve DiMattia,
+1-646-201-5445, all of EVC Group for Delcath Systems, Inc. Web
Site: http://www.delcath.com/
Copyright